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Abstract
Background: Our previous studies showed that Salvianolic acid B (Sal B) inhibited 7,12-dimethylbenz[a]anthracene
(DMBA)-induced oral carcinogenesis in hamsters and such anti-cancer effects might be related to the inhibition of
angiogenesis. This study was aimed to further investigate the anti-proliferative effect of Sal B on the most common
type of oral cancer, oral squamous cell carcinoma (OSCC) and the possible mechanisms of action with respect to
angiogenesis inhibition.
Methods: Two well-characterized oral squamous cell carcinoma cell lines, CAL27 and SCC4, and premalignant
leukoplakia cells were treated with different concentrations of Sal B. Cytotoxicity was assessed by MTT assay. cDNA
microarray was utilized to evaluate the expression of 96 genes known to be involved in modulating the biological
processes of angiogenesis. Real-time reverse transcription-polymerase chain reaction analysis was conducted to
confirm the cDNA microarray data.
Results: Sal B induced growth inhibition in OSCC cell lines but had limited effects on premalignant cells. A total of
17 genes showed a greater than 3-fold change when comparing Sal B treated OSCC cells to the control. Among
these genes, HIF-1a, TNFa and MMP9 are specifically inhibited, expression of THBS2 was up-regulated.
Conclusions: Sal B has inhibitory effect on OSCC cell growth. The antitumor effect can be attributed to anti-
angiogenic potential induced by a decreased expression of some key regulator genes of angiogenesis. Sal B may
be a promising modality for treating oral squamous cell carcinoma.
Background
Carcinomas of the oral cavity, especially oral squamous
cell carcinoma (OSCC), have become an important
healthcare problem worldwide. Survival rate of oral car-
cinoma is lower than most other carcinomas, and has
not been improved substantially in past years. The con-
ventional treatment is a combination of surgery, radia-
tion therapy and chemotherapy. Among these strategies,
chemotherapy is beneficial for local control and survival
improvement. Nevertheless, treatment with current che-
motherapeutic drugs does not always substantially
induce a positive response. Therefore, finding an effec-
tive therapeutic and preventive strategy for patients of
such malignancy is of utmost importance. Screening
Chinese medicine herbs or their extracts is believed a
promising strategy to find effective chemopreventive
agents.
Angiogenesis, the growth of new capillaries from pre-
existing blood vessels, is essential for cancer to grow
beyond minimal size and metastasize [1,2]. Anti-angio-
genesis remains a prime therapeutic target and anti-
angiogenic therapy may be less susceptible to develop
treatment resistance. Thus screening natural health pro-
ducts that inhibit angiogenesis is a potential source for
investigating new agents to treat oral cancer.
Salvia miltiorrhiza (Danshen), a popular Chinese herb,
has been widely and successfully used for treating
angina pectoris, myocardial infarction (MI) and stroke
[3]. Salvianolic acid B (Sal B), one of the major water-
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and bioactive member of the salvianolic acids in Danshen
(exhibiting antioxidant, hepatoprotective and many other
actions) [4]. Studies have shown that Sal B possesses
many biological activities of the Danshen herb. For exam-
ple, it was reported to possess anti-inflammatory and
anti-oxidative properties, modulation of apoptosis, inhibi-
tion of platelet aggregation, improved coronary microcir-
culation [5-8]. It was also reported that Sal B enhanced
angiogenic processes on SVR cells through up-regulation
of VEGF and VEGF receptors genes [9], enhanced angio-
genesis in vitro and improved skin flap survival in Spra-
gue-Dawley rats [10], and improved the integrity of
microvessels after ischemia [11]. But our previous studies
showed that Sal B significantly decreased the squamous
cell carcinoma (SCC) incidence from 64.7 (11/17) to
16.7% (3/18), with a simultaneous decrease in the immu-
nostaining of HIF-1a and VEGF protein [12]. These find-
ings suggest that Sal B may serve as a preventive and/or
therapeutic agent against oral cancer. And inhibition of
angiogenesis may be one of the mechanisms of action.
This encouraging in vivo result prompted us to further
investigate how Sal B affects oral squamous carcinoma
cells growth and prohibits new vessels formation.
Methods
Drugs and Reagents
Sal B was a generous gift from Prof. Wei-dong Zhang,
Department of Medicinal Chemistry of Nature Product,
School of Pharmacy, Second Military Medical Univer-
sity, Shanghai, China. The purity of Sal B was 98%
(determined by high-performance liquid chromatogra-
phy method with fluorescence). Its molecular weight is
718, and its molecular formula is C36H30O16. Sal B was
dissolved in double distilled H2O at a concentration of
200 mM, filtered through a 0.22 μm filter, and stored at
-70°C. The stock solution was freshly diluted to the
desired concentrations with medium immediately before
use. Dulbecco’s modified Eagle’s medium (DMEM) and
fetal bovine serum (FBS) were obtained from GIBCO
BRL (Grand Island, NY, USA). 3’-(4,5-dimethylthiazol-2-
yl)-2, 5-diphenyl tetrazolium bromide (MTT) was pur-
chased from BD Pharmingen (USA).
Cell lines
Three cell lines were used in this study, including
CAL27, SCC4 and Leuk1. CAL27 and SCC4 were pro-
vided by Laboratory of Oral Tumor and Oral Biology,
Shanghai Key Laboratory of Stomatology, Shanghai,
China. Leuk1 was a gift from Prof. Li Mao of University
of Maryland Dental School, Baltimore, USA. Leuk1 and
CAL27 cells were cultured in DMEM (Invitrogen) med-
ium supplemented with 10% (v/v) fetal bovine serum,
100 units/ml penicillin and 100 units/ml streptomycin
(GIBCO). SCC4 cells were maintained in DMEM/F12
supplemented with 10% FBS, 100 units/ml penicillin and
100 units/ml streptomycin. All cells were maintained in
a humidified atmosphere of 5% CO2 at 37°C.
Cell viability assay
The inhibitory effect of Sal B on the cell viability was
measured by MTT colorimetric method. Cells were pla-
ted into a 96-well plate at a density of 1 × 10
3/well in
96-well tissue culture plates. On day two, cells were
treated with increasing doses of Sal B (50, 100, 200 ug/
ml) for 24 h, 48 h and 72 h. After drug treatment,
attached cells were incubated with MTT (0.5 mg/ml, 1
h) for 4 hours and subsequently solubilized in DMSO.
The absorbance of each well was measured using an
enzyme-linked immunosorbent assay reader at 490 nm.
Experiments were performed at least three times.
Nucleic acid isolation and cDNA probe preparation
Total RNA was isolated from cell culture flasks using
RNAbee (Biogenesis), purified using chloroform, precipi-
tated using cold isopropanol, washed using 75% ethanol.
The resulting RNA concentration was measured spec-
trophotometrically and the quality of RNA was con-
firmed in agarose gels. cDNA for each sample was
obtained by RT-PCR from 500 μgR N Ai nt h ep r e s e n c e
of Biotin-16-dUTP (Roche Cat. No.1-093-070). Briefly,
RNAs were denatured at 70°C for 10 min and cDNAs
were synthesized at 42°C by oligo-dT priming in a final
volume of 30 μl. The labelled cDNAs were purified by
spin column chromatography. Then, the biotin-labeled
cDNA was fragmented by incubation in fragmentation
buffer at 94°C for 5 min and chilled on ice.
cDNA microarray analysis
GEArray Q Series Angiogenesis Gene Array HS-009
(SuperArray Bioscience), containing 96 genes known to
be involved in modulating the biological processes of
angiogenesis, was prehybridized at 68°C for at least 90
min before probe addition in hybridization buffer. Then,
the fragmented labeled cDNA was applied to the buffer.
Hybridization was performed at 60°C overnight in a roll-
ing bottle. The arrays were washed twice with 2 × SSC
and 0.5% SDS at 60°C for 30 min; followed by two strin-
gent washes with 0.5 × SSC, 0.5% SDS at the same tem-
perature and for the same length of time. Finally, damp
arrays were sealed in plastic wrap and exposed to ima-
ging plates (BASMP 2040S; Fuji, Nakamura, Japan) for
24 hours, which were then scanned with a HP GeneAr-
ray Scanner (Hewlett-Packard, Palo Alto, CA).
Microarray data analysis
GEArray Analyzer software was used for background
subtraction and data normalization. Each GEArrayTM
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trols (pUC 18 DNA and blanks) and housekeeping
genes, including b-actin, GAPDH, cyclophinin A and
ribosomal protein L13a. All raw signal intensities should
be corrected for background by subtracting the mini-
mum value to avoid the appearance of negative num-
bers. All signal intensities should also be normalized to
that of a housekeeping gene. These corrected, normal-
ized signals can then be used to estimate the relative
abundance of particular transcripts.
Real-time reverse transcription-polymerase chain reaction
(RT-PCR) analysis
The total RNA prepared for microarray analysis was also
used for RT-PCR analysis of selected genes. Total RNA
(2 μg) from each sample was subjected to reverse tran-
scription using a Superscript first strand cDNA synthesis
kit (Invitrogen) according to the manufacturer’sp r o t o -
col. Real-time PCR reactions were then carried out in a
25 μL reaction mixture (1 μL of cDNA, 12.5 μLo f2 X
SYBR Green PCR Master Mix, 1 μLo f2 0μM specific
gene primer pair, 2.5 μL of PCR buffer, 3 μLo fM g C L 2
solution, 3 μL of dNTP solution, 3 units of Taq and 2 3
μLo fH 2O) in an Rotor-Gene 3000 Realtime PCR
machine (Corbett Research). The PCR program was
initiated by 2 min at 50°C and 10 min at 95°C before 40
thermal cycles, each of 20 s at 94°C and 30 s at 72°C.
Data were analyzed according to the comparative cycle
threshold (Ct) method and were normalized by b-actin
expression in each sample. Melting curves for each PCR
reaction were generated to ensure the purity of the
amplification product.
Statistical analysis
The significance of results obtained from the control
and treated groups was analyzed using the paired Stu-
dent’s t-test. Means and standard deviations were calcu-
lated. P < 0.05 was regarded as statistically significant.
Results
Effects of Sal B on cell viability
We evaluated the effects of Sal B on cell growth in the
human oral squamous cell carcinoma cell lines CAL27,
SCC4 and immortalized oral leukoplakia cell line Leuk1.
Cells were incubated with increasing doses of Sal B (50,
100, 200 μM) or vehicle control for 24, 48 h and 72 h
respectively; and cell viability was determined by a con-
ventional tetrazolium-based (MTT) assay. As shown in
Figure 1A and 1B, Time-dependent growth inhibition
was seen in CAL27 cells. The SCC4 cells seemed to be
stimulated after 24 hour, but moderate inhibited at
higher concentration after 48 h and inhibited after 72 h.
The IC50 values were 51 μg/ml and 87 μg/ml,
respectively. In contrast, Sal B had a limited effect on the
growth of Leuk1 (Figure 1C).
Expression Profiling of Sal B treated cells
We analyzed the gene expression profiles of Sal B trea-
ted CAL27 and SCC4. In comparison of Sal B treated
cells with the control, we identified only two genes of
which the scaled average difference values varied by ≥3-
fold in both of the OSCC cell lines. One is down-regu-
lated hypoxia inducing factor 1a (HIF-1a), the other one
is up-regulated Thrombospondin-2 (THBS2). Then we
relaxed the stringency of our selection criteria to iden-
tify genes that exhibited a 3-fold expression difference
in Sal B treated CAL27 or SCC4 cells relative to the
control cells. The results demonstrated that 17 genes
showing a greater than 3-fold change after Sal B treat-
ment. Among these, 15 genes were down-regulated and
2w e r eu p - r e g u l a t e d( T a b l e1 ,T a b l e2a n dF i g u r e2 ) .
Genome profiles are available online through the NCBI
Gene Expression Omnibus http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE29416SE29416.
Target verification by RT-PCR
To verify the alterations of gene expression at the
mRNA level, which appeared on the microarray, we
chose four genes (HIF1a,T N F a, MMP9, THBS2) with
varying expression profiles for real-time RT-PCR analy-
sis. The results of real-time RT-PCR analysis for these
selected genes were consistent with the microarray data.
Gene expression alterations were similar by real-time
RT-PCR analysis, although the fold changes in the
expression level differed somewhat in the two analytical
methods (Figure 3).
Discussion
Clinical practice for years has proven that Salvia miltior-
rhiza has anti-cancer potential and its application in the
treatment of a variety of cancers has achieved surprising
effects [13,14]. However, most of the studies about Sal
B, one of the major biologically active components of
Salvia miltiorrhiza, were focused on its effects on cardio-
v a s c u l a rd i s o r d e r s .T h e r ea r ef e wd a t aa v a i l a b l ea b o u t
the effect of this component on cancer. It was for this
reason that Sal B was evaluated in our study for its che-
mopreventive and chemotherapeutic potential against
OSCC.
In the present study we investigated whether Sal B has
any inhibitory properties on OSCC cells and potentially
malignant Leuk1 cells, in order to provide more docu-
m e n t a t i o no nt h ep o s s i b l ea p p l i c a t i o no fS a lBo n
OSCCs and oral premalignant lesions. We have shown
that Sal B potently inhibited cell growth and induced
apoptosis in OSCC cell lines CAL27 and SCC4. How-
ever, Sal B was much less active in Leuk1. The
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Page 3 of 8Figure 1 Effects of Sal B on growth of human oral squamous cell carcinoma cells CAL27, SCC4 and oral precancerous cells Leuk1. Cells
(1 × 10
4) were treated with increasing concentrations of Sal B (50, 100,200 μg/mL) for 72 h. Viable cells were measured by MTT assay and
expressed as a percentage of control. All values are means of three independent experiments ± SD (bars). Time-dependent growth inhibition
was seen in CAL27 cells. The SCC4 cells seemed to be stimulated after 24 h, but moderate inhibited at higher concentration after 48 h and
inhibited after 72 h. No growth inhibition was also seen in Leuk1 cells. The significance of results obtained from the control and treated groups
was analyzed using the paired Student’s t-test. Means and standard deviations were calculated. P < 0.05 was regarded as statistically significant.
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tion need to be further investigated. It needs to be
noted that Sal B undergoes degradation in normal saline
solution which will affect its anti-cancer effect. But we
found in this study that Sal B still significantly inhibited
the growth of CAL27 and SCC4 cells after treatment
over 24 hours. We suppose its anti-cancer effect will be
more potent if Sal B could be used in a solid state.
Results of another study from this laboratory showed
that the growth inhibitory effect of Sal B was related to
the apoptosis-inducing effect of Sal B (determined by
flow cytometry analysis, data not shown). The detailed
mechanism(s) of the pro-apoptotic effect of Sal B on
OSCC cells remains unclear, as we have not attempted
to investigate this aspect of action in this study. But this
finding, together with our previous in vivo results, sug-
g e s t st h a tS a lBm a yb eag o o dc a n d i d a t ef o rt h e r a p yi n
patients with these malignancies.
Further microarray-based expression profiling and
quantitative RT-PCR analyses were performed to con-
firm whether anti-angiogenesis is one of the possible
mechanisms of Sal B-induced growth inhibition in
CAL27 and SCC4 cells, the two OSCC cell lines sensi-
tive to the growth inhibitory effects of Sal B. The
results showed that HIF-1a is down-regulated by ≥3-
fold in both of the Sal B treated CAL27 cells and
SCC4 cells. This result was consistent with our pre-
vious immunostaining studies. In our previous study,
we observed that the formation of microvessels, as well
as the expression of pro-angiogenic factors HIF-1a and
VEGF, was inhibited in dysplasia and SCC by Sal B
[12]. HIF-1a is a transcription factor activated in
response to cellular hypoxia. Being stabilized under
decreased tissue oxygen concentration, it works as a
cellular oxygen-sensing system, and trans-activates a
large number of genes. Included among these are ery-
thropoietin, glucose transporters, glycolytic pathway
enzymes, and inducible nitric oxide synthase [15-17].
Discoveries have shown that hypoxia activates HIF-1a,
which functions as master switches to induce expres-
sion of several angiogenic factors including VEGF,
nitric oxide synthase (NOS), platelet-derived growth
factor (PDGF) and Ang2. Alteration and over-expres-
sion of HIF-1a has been detected in a variety of solid
tumors, including breast, lung, ovarian and oral cancer
[18,19]. These observations, together with our results,
strongly implied that inhibition of HIF-1a activation
by Sal B, which resulted in lowered expression of
downstream pro-angiogenic genes, may be a key
mechanism of cell growth inhibition and anti-angio-
genesis on oral cancers. Their relative protein expres-
sion levels and whether such an action can be
demonstrated in vivo remains to be confirmed.
However, the anti-angiogenic effect of Sal B seemed
contradictive to some previous studies which showed
that Sal B might improve microcirculation by augment-
ing VEGF expression and promoting angiogenesis.
[9-11,20]. Thrombospondins (TSPs) are known to inhi-
bit neovascularization by induction of endothelial cell
apoptosis through interaction with CD36 [21], inhibition
of metalloproteinase activity [22], and inhibition of cell-
cycle progression [23]. In addition to these well-known
effects on endothelial cell proliferation and apoptosis,
maintenance of vascular integrity is another notable
function of TSPs [24-26]. In this study, thrombospon-
din-2 (THBS2) expression was up-regulated by ≥3-fold
in both of the Sal B treated CAL27 cells and SCC4 cells.
Another study in our lab showed that in the Sal B trea-
ted samples, the mural cell coverage index was signifi-
cantly higher than that of the control. And the
organization of mural cells in the two groups of samples
was dramatically different (data not shown). This sug-
gests that Sal B may prevent the formation of new ves-
sels by promoting vascular maturation. It is possible
that the pro-angiogenic effect of Sal B induces formation
of mature vessels with efficient irrigation function. The
Table 1 Angiogenesis-related Genes Significantly
Affected by Sal B in CAL27 cells
gene code Mean fold difference










Up-regulated THBS2 NM_011581 3.42
Table 2 Angiogenesis-related Genes Significantly
Affected by Sal B in SCC4 cells
gene code Mean fold difference
Down-regulated HIF-1a NM_010431 5.75
Mmp9 4.17







Up-regulated THBS2 NM_011581 3.23
Timp1 NM_011593 3.15
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tumors which leads to the formation of a poorly orga-
nized vasculature characterized by tortuous and leaky
vessels unable to support efficient blood flow (Further
investigation will carried out to clarify this point). The
potent effect of Sal B on blood circulation may reduce
the hypoxia stress in the local tissues, thus inhibit the
uncontrolled formation of leaky vasculature. Based upon
this information, the current results may be in line with
those of previous studies.
Several angiogenesis-associated genes, including
Tenascin-C, Osteopontin, TGF-b1,C o x - 2 ,H G F ,M M P - 2
and MMP-9 also displayed variable expression in this
study. Expression of these genes was changed ≥3-fold in
CAL27 cells or SCC4 cells. This result was consistent
with earlier studies which reported that Sal B attenuates
LPS-induced Cox-2, MMP-2 and MMP-9 expression in
human aortic smooth muscle cells. [27,28] We found
that these genes also play important roles in other ways
that can affect cell signaling, the apoptotic pathway, cell
metastasis, and other cellular behaviors. For example,
expression of COX-2 was inhibited in Sal B treated
OSCC cells. Over-expression of COX-2 is thought to
contribute to carcinogenesis by stimulating cell prolif-
eration [29], inhibiting apoptosis [30], and enhancing
angiogenesis [31]. Such genes as Tenascin-C, Osteopon-
tin and MMP, which were reported to contribute to
tumor metastasis [32-35], were inhibited by Sal B in this
study. Therefore, this suggested that Sal B may exert
multiple effects on oral carcinogenesis. Further research
is required to investigate whether other mechanisms, as
anti-metastasis, anti-oxidant and anticoagulation effect,
will contribute towards the chemopreventive effect of
Sal B on OSCC cells.
Conclusion
Our study suggests that Sal B has cytotoxic effect on
OSCC cells. Its antitumor effect could be attributed to
its anti-angiogeneic effect. Sal B may function by inhibit-
ing expressions of such angiogenesis-associated genes as
HIF-1a, THBS2, Tenascin-C, Osteopontin, TGFb1, Cox-
2, HGF, and MMP2. Translational investigations to
determine whether these angiogenesis-associated genes
are regulated by Sal B in OSCC tumors in vivo and
Figure 2 The differential gene expression between the positive control and Sal B treated OSCC. The crosses show the magnitude of
differential expression between the positive control and Sal B treated OSCC. Red = the positive control; Green = Sal B treated OSCC.
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should further elucidate the mechanisms of action of
this new agent in OSCC.
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